VKTX Viking Therapeutics Inc

$VKTX The Abbvie CEO explicitly stated the were look for GLP medicines that could compliment the half life of their Amylin asset ABBV-295. ABBV-295 has a half life ~ 11 days VK2735 has a half life ~ 9 days No other late stage dual/triple agonist has a half life as long as VK2735… Was ABBV a bidder for MTSR???

$VKTX Investing in $VKTX for the long term is a no-brainer. People are only complaining because they’re chasing quick profits instead of focusing on the bigger picture. VKTX has the potential to deliver at least 5x our investment. Stay patient, trust the process, and let the long-term vision play out.

$VKTX Oral maintenance trial… When in the last 8 years has Viking ever done such close back to back trials? Despite this, PO maintenance trial enrollment initiation was announced 14 days after SQ results.. This is especially interesting considering the PO trial won’t conclude at least until Q3 2028 at the soonest (PO maintenance results will be at least a year earlier). The PO maintenance trial is important but not simply about maintenance, it’s more about proving TOLERABILITY to BP prior to a buyout/merger. This is why they moved to start PO maintenance so quickly IMO ☝️☝️☝️☝️ Buyout window starts after Vanquish 1 and PO maintenance is what drives the multiple. Wall St realizes this and will add going forward unfortunately retail has no clue and want to sell for $50/share, ridiculous and myopic 😒

$VKTX ABBV talking about purchasing bolt on obesity assets depending on efficacy and tolerability during their Q&A portion of earnings just now.Plenty of BP's looking.I think our chances of buyout early 2027 are increasing substantially.might be a bumpy ride but will be worth the wait.

$VKTX little shorts here are frantic on 6% move up. Let us watch their reaction to 200% up in one day between tomorrow and q3 -2027. They believe technicals like last few wks will help them out. Wrong.

$VKTX Viking has traded 450% of the total dollar volume of GPCR, ALT, KLRA today combined. The market has long decided that VKTX has the most distributive GLP agonist in late development. It will also be next dual agonist to market. If NVO thought MTSR was only worth $10 billion and they have decreed that they plan on doing M&A activity in the not too distant future; what, other company currently could they be referring to with a $20 billion plus buyout? Post ph3 results IMO…

$VKTX -It should be painfully obvious by now that BL with his investment banking background really doesn't give a hang about what a bunch of retail amateurs think about his style on a social media platform. He is catering to the investment banks and institutional investorswho could care less if he uhs and uhms. They want results and they want to sell stock and make deals.They are the ones who have the ear of Big Pharma, not the trader on E-Trade who buys 10 put or calls for Friday's expiration. Retail to BL are a bunch of gnats that just happen to be in the way. The fact that conference calls have a dozen analysts from the biggest firms just reinforces who the real clients are. Moaning about it might make you feel better but won't help. Thinking S/T posters are going to incite a coup is just folly. We are the only ones worried about the short term price. Isn't it just so obvious? I' m betting with my own capital that the BOD is playing to the right audience.

$VKTX yesterday and today actions show some institutions can see the obvious potential that many of us easily notice at this point. This mid day low volume action is meaningless, will close green today. Too cheap to ignore. Late phase 3.

$VKTX Yes. AbbVie (ABBV) made some very interesting comments today, October 30, 2026, about expanding its obesity and GLP-1 business. This is particularly interesting when looking at companies such as Viking Therapeutics (VKTX). What AbbVie said today During its third-quarter earnings call: AbbVie said it wants to expand its presence in the obesity market. Management expects future acquisitions to be more like bolt-on deals, rather than enormous transformational acquisitions. AbbVie is interested in early-stage, late-stage and already-marketed drugs. Its chief medical officer specifically said it is open to acquiring differentiated obesity drugs, including incretin-based treatments that could be combined with its existing drug ABBV-295. 

$VKTX - Now many hedgies are realizing why they raised cash (given 4 Phase 3 trials, 2 Phase 1 Trial ongoing, cost is going to go higher -but pipeline potential goes up by many fold with higher probability of success), and that too they raised with minimum dilution (even if have to offer at discounted price - but still high at 35) and raising half with debt note with conv price of 53. AND Oral Phase 3 study one will finish enrollment in a blink (like in Jan or at the most in Feb) as it is just 560 subjects and people know it works. 2nd study will also recruit fast as it is 560 patients (but will take some time as it is Diabetic patients). And this will be a surprise good news when they announce completion of enrollment so fast in Sunrise 1. Very

$VKTX Folks will take every break in the action to piss on BL, scrutinizng every word, reading heavily into every stammer. Hedgers manipulate the SP and triple down on every negative urge to embolden the trash-talkers. And then Lilly reports GLP-1 earnings and all these naysayers suddenly clam up. If VK2735 can pull $10B revs - which is very doable in an expanding market with increasing indications and the time-value of money making $10B in the early 2030s closer to $6B-$7B today, we're looking at a MC easily exceeding $100B by that time. Increase the outstanding shares by, say, 20% from today, roughly 150M shares, that translates to a SP of about $667 PPS. This isn't a "sunny day" scenario, folks. It is actually very conservative, and the reality could easily be double that. Who's buying, now? Long hold. Insanely...

$VKTX It’s so painful watching Jim Cramer. I like to listen to pre-market CNBC in the morning but it’s torture to listen to him especially today as his top pick Intel is in the 🚽 and he was very wrong. Hopefully people don’t follow his investing advice.

$VKTX there is no way that the BP players: 1. aren't noticing what is going on with LLY 2. are going to let VKTX sell on the cheap 3. aren't having their scientist Due Diligence teams poring over every single VKTX document. I just don't think the company isn't acquired in the next 6-12 months...the TAM is just too huge to not want to have a great drug in the portfolio

$VKTX 2027 Catalyst Calendar Q1 * Jan 11–14: J.P. Morgan Healthcare Conference. * VK3019: Phase 1 MAD starts; possible SAD data. * VANQUISH-1/2: 52-week extensions begin. * Feb (est.): 2026 annual/Q4 earnings. Q2 * Apr–May (est.): Q1 earnings. * May 18–21: European Congress on Obesity.* * May (est.): VK2735 Maintenance Part 2 primary completion. * Jun 18–21: ADA Scientific Sessions.* * Possible VK3019 MAD updates. Q3 * Jul (est.): VANQUISH-1/2 Phase 3 primary completion. * Jul (est.): VK2735 Maintenance Part 2 completion. * Jul–Aug (est.): Q2 earnings. * H2: Potential VANQUISH-1/2 Phase 3 topline results. Q4 * Oct–Nov (est.): Q3 earnings. * Nov 8–11: ObesityWeek.* * 2027: Maintenance Part 2 results; SUNRISE-1/2 enrollment updates; further VK3019 data. Other Potential Catalysts * VK2809/VK0214 partnerships * VK2735 strategic partnership or acquisition * New clinical publications and FDA meetings * Manufacturing/supply agreements * Commercial expansion and investor conferences

$VKTX you just can't take a chance and not be holding through the weekend ..... Anything can happen on Monday morning

U got people commenting on a mature phase 3 trial where all pts received > 1 year of $VKTX 2735 as long way to go while others such as $AZN , $NVO etc are doing preclinical deals.😂 $ABBV that is looking at obesity as its primary growth driver barely started phase 2 with a mediocre asset. Who cares about commercializing or not. Worst case just wait for phase 3 and either stay or get out.

$VKTX – Remaining Catalysts for 2026 November * Nov 10–12: Stifel Healthcare Conference. * Nov 12: Truist BioPharma Symposium. * Nov 14: ObesityWeek – VANQUISH-2 data presentation. * Nov 15: ObesityWeek – New VK2735 (VENTURE) analyses. * Nov 16–17: UBS Global Biopharma Conference. * Nov 16–19: Jefferies Global Healthcare Conference. December * Dec 1–3: Piper Sandler Healthcare Conference. * Q4: Expected completion of VK3019 Phase 1 SAD study. Other Potential Catalysts (No Confirmed Dates) * Partnership agreements for VK2809 and VK0214. * VANQUISH and SUNRISE updates. * Potential strategic partnership for VK2735. * Manufacturing and commercialization developments. * Potential acquisition of Viking.

$VKTX Just because the full phase 3 readout is in 7-8 months doesn’t mean this is dead money for that time period. I get the sense people think it’s going to be another massive wait. The first people coming off the initial 72 week trial starts in January and I guarantee there will be BPs lined up to know what those numbers look like as they become statistically significant. This will start cooking here faster than you think.

$VKTX Cannot be more bullish than that: Canaccord Genuity raises its price target for Viking Therapeutics (VKTX) to $118 from $106 today. Source: Reuters, October 29, 2026

$VKTX if Metsera got a BO for 10 Billion we are worth AT A MINIMUM 17.5 billion on a BO RIGHT NOW Phase 3 is a major success you can double that price for a BO